Blog Posts
Teliso-V and osimertinib: the METamorphosis of EGFR-mutant lung cancer?
Sour

Teliso-V and osimertinib: the METamorphosis of EGFR-mutant lung cancer?

Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X:

“Teliso-V and osimertinib: the METamorphosis of EGFR-mutant lung cancer?

Performing biopsies at treatment resistance is crucial to aid drug development and should be encouraged.”

Teliso-V and osimertinib: the METamorphosis of EGFR-mutant lung cancer? – Annals of Oncology

Authors: J. Remon, S.P.L. Saw

Teliso-V and osimertinib: the METamorphosis of EGFR-mutant lung cancer?

 

cancer Hidehito Horinouchi J. Remon OncoDaily Oncology S.P.L. Saw